CStone Pharmaceuticals
Shanghai
China
About CStone Pharmaceuticals
CStone Pharmaceuticals Co., Ltd. engages in the research and development of immuno-based combination therapeutics for oncology, cardiovascular diseases, rheumatoid arthritis, hematology and autoimmune diseases. The company is based in China.YEAR FOUNDED:
July 2016
LEADERSHIP:
CEO: Frank Jiang, MD, PhD
95 articles with CStone Pharmaceuticals
-
CStone presents updated results of a registrational study of sugemalimab in patients with stage III NSCLC via oral presentation at WCLC 2022
8/8/2022
CStone Pharmaceuticals, announced the presentation of the final progression-free survival analysis results from the registrational GEMSTONE-301 study of sugemalimab as a consolidation therapy in patients with unresectable stage III non-small cell lung cancer whose disease had not progressed after concurrent or sequential chemoradiotherapy at the IASLC 2022 World Conference on Lung Cancer.
-
Unnamed sources “familiar with the matter” informed Bloomberg that CStone's leadership team is working with Goldman Sachs to determine if there are interested buyers.
-
CStone and Pfizer announce NMPA approval of sugemalimab in patients with unresectable stage III non-small cell lung cancer
6/6/2022
CStone Pharmaceuticals and Pfizer Inc. announced that the National Medical Products Administration of China has approved sugemalimab for the treatment of patients with unresectable stage III non-small cell lung cancer whose disease has not progressed following concurrent or sequential platinum-based chemoradiotherapy.
-
CStone announces first patient enrollment in the U.S. in the Phase 1 clinical trial of CS5001, a potential global best-in-class ROR1-targeting ADC
3/30/2022
CStone Pharmaceuticals ("CStone", HKEX: 2616), a leading biopharmaceutical company focused on the research, development, and commercialization of innovative immuno-oncology therapies and precision medicines, today announced that the first patient has been enrolled in the U.S. in the Phase 1 clinical trial for CS5001.
-
Ligand will spin off its antibody discovery business into a new entity known as OmniAb, Inc., which will then merge with Avista Capital Partners and head to The Nasdaq Stock Market.
-
Clinical Catch-Up: January 17-21
1/24/2022
Last week was a relatively quiet week for clinical trial news, particularly around COVID-19. Here’s a look. -
CStone announces the GEMSTONE-302 study of sugemalimab met the endpoint of overall survival in the first-line treatment of metastatic non-small cell lung cancer patients
1/19/2022
CStone Pharmaceuticals, a leading biopharmaceutical company focused on research, development, and commercialization of innovative immuno-oncology therapies and precision medicines, announced that the GEMSTONE-302 registrational clinical study of sugemalimab for the first-line treatment of metastatic non-small cell lung cancer met the overall survival endpoint.
-
A checkpoint inhibitor under development from China’s CStone Pharmaceuticals hit the mark in a Phase III non-small cell lung cancer study.
-
CStone Pharmaceuticals announced the IND approval of CS5001, a potential global best-in-class ROR1-targeting ADC by the U.S. Food and Drug Administration
1/3/2022
CStone Pharmaceuticals announced that the investigational new drug application of CS5001, a potential global best-in-class antibody-drug conjugate targeting receptor tyrosine kinase-like orphan receptor 1 has received a STUDY MAY PROCEED letter from the U.S. Food and Drug Administration.
-
Today, the FDA approved two new drug applications. One is for Spero's tebipenem HBr oral tablets and the second is CStone's IND application for CS5001.
-
Ligand’s Partner CStone Pharmaceuticals Receives Approval in China for Sugemalimab (Cejemly®) for the First-Line Treatment of Advanced Non-Small Cell Lung Cancer in Combination with Chemotherapy
12/22/2021
Ligand’s Partner CStone Pharmaceuticals Receives Approval in China for Sugemalimab (Cejemly ® ) for the First-Line Treatment of Advanced Non-Small Cell Lung Cancer in Combination with Chemotherapy.
-
CStone announced New Drug Approval of Cejemly® (Sugemalimab) in China to Potentially Reshape The Landscape of Immuno-oncology Therapy in Lung Cancer
12/21/2021
CStone Pharmaceuticals is pleased to announce that the National Medical Products Administration of China has approved the new drug application of anti-PD-L1 monoclonal antibody Cejemly® in combination with chemotherapy for treatment-naïve metastatic non-small cell lung cancer patients.
-
CStone forged a licensing agreement with Jiangsu Hengrui Pharmaceuticals that grants the company access to a monoclonal antibody aimed at multiple forms of cancer.
-
CStone Pharmaceuticals and Jiangsu Hengrui Pharmaceuticals announce strategic partnership and exclusive licensing agreement on anti-CTLA-4 monoclonal antibody CS1002 in Greater China
11/21/2021
CStone Pharmaceuticals, a leading biopharmaceutical company focused on the research, development, and commercialization of innovative immuno-oncology therapies and precision medicines, and Jiangsu Hengrui Pharmaceuticals announced a strategic partnership and exclusive licensing agreement on anti-CTLA-4 mAb CS1002 in the Greater China region.
-
The deal will give EQRx a pre-transaction enterprise value of $3.65 billion and an immediate $1.8 billion in cash that will be used to advance the development of the company’s pipeline.
-
Primary Endpoint Met in Phase 3 Study of the Anti-PD-L1 Antibody Sugemalimab in Stage III Non-Small Cell Lung Cancer
5/28/2021
Sugemalimab is the first PD(L)1 monoclonal antibody to demonstrate a progression-free survival benefit in Stage III non-small cell lung cancer (NSCLC) patients after treatment with either concurrent or sequential chemoradiotherapy
-
CStone and LegoChem Biosciences Enter Global Licensing Agreement for New Antibody Drug Conjugate
10/28/2020
CStone Pharmaceuticals ("CStone", HKEX: 2616) announced today a licensing agreement with LegoChem Biosciences, Inc. ("LCB", KOSDAQ:141080), for the development and commercialization of LCB71, a potential first-in-class/best-in-class antibody drug conjugate ("ADC").
-
CStone Announces Completion of $200 million Share Sale to Pfizer
10/12/2020
CStone Pharmaceuticals announced the completion of the Share Subscription Agreement through which an affiliate of Pfizer Inc. subscribed for newly issued CStone shares at approximately US$200 million, bringing into effect the multifaceted strategic collaboration that the companies announced on September 30, 2020.
-
CStone, Pfizer Enter into Strategic Collaboration to Address Oncological Needs in China
9/30/2020
Pfizer to invest $200 million in CStone shares and license CStone’s late-stage oncology asset sugemalimab (CS1001, PD-L1 antibody) in mainland China
-
Pfizer invested $200 million into the company for a nearly 10% stake to support the development of a checkpoint inhibitor aimed at the oncology market in China.